In the NSCLC-BM cohort, significantly higher frequencies of several targetable GAs were present when compared with pNSCLC, including ALK fusions (2.7% [83/3,035] vs 1.7% [123/7,277]), KRAS G12C mutations (15.2% [460/3,035] vs 11.7% [853/7,277]), and MET amplifications (4.4% [133/3,035] vs 2.3% [170/7,277]) (all P < .05; Table 2). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.